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Abstract
Objective To summarize short term outcomes in randomized controlled
trials comparing glibenclamide or metformin versus insulin or versus
each other in women with gestational diabetes requiring drug treatment.
Design Systematic review and meta-analysis.
Eligibility criteria for selecting studies Randomized controlled trials
that fulfilled all the following: (1) published as full text; (2) addressed
women with gestational diabetes requiring drug treatment; (3) compared
glibenclamide v insulin, metformin v insulin, or metformin v glibenclamide;
and (4) provided information on maternal or fetal outcomes.
Data sources Medline, CENTRAL, and Embase were searched up to
20 May 2014.
OutcomesmeasuresWe considered 14 primary outcomes (6 maternal,
8 fetal) and 16 secondary (5 maternal, 11 fetal) outcomes.
Results We analyzed 15 articles, including 2509 subjects. Significant
differences for primary outcomes in glibenclamide v insulin were obtained
in birth weight (mean difference 109 g (95% confidence interval 35.9 to
181)), macrosomia (risk ratio 2.62 (1.35 to 5.08)), and neonatal
hypoglycaemia (risk ratio 2.04 (1.30 to 3.20)). In metformin v insulin,
significance was reached for maternal weight gain (mean difference
−1.14 kg (−2.22 to −0.06)), gestational age at delivery (mean difference
−0.16 weeks (−0.30 to −0.02)), and preterm birth (risk ratio 1.50 (1.04
to 2.16)), with a trend for neonatal hypoglycaemia (risk ratio 0.78 (0.60
to 1.01)). In metformin v glibenclamide, significance was reached for
maternal weight gain (mean difference −2.06 kg (−3.98 to −0.14)), birth
weight (mean difference −209 g (−314 to −104)), macrosomia (risk ratio
0.33 (0.13 to 0.81)), and large for gestational age newborn (risk ratio
0.44 (0.21 to 0.92)). Four secondary outcomes were better for metformin
in metformin v insulin, and one was worse for metformin in metformin v
glibenclamide. Treatment failure was higher with metformin than with
glibenclamide.
Conclusions At short term, in women with gestational diabetes requiring
drug treatment, glibenclamide is clearly inferior to both insulin and
metformin, while metformin (plus insulin when required) performs slightly
better than insulin. According to these results, glibenclamide should not
be used for the treatment of women with gestational diabetes if insulin
or metformin is available.
Systematic review registration NCT01998113
Introduction
Gestational diabetes is a common complication of pregnancy,
and prevalence is increasing.1 The standard therapy for women
with gestational diabetes requiring drug treatment is insulin.
However, since the seminal trial by Langer et al comparing
glibenclamide (glyburide) with insulin,2 oral agents have been
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increasingly viewed as potential alternatives. Several
observational and randomized controlled trials have addressed
the use of oral agents in gestational diabetes, mainly
glibenclamide andmetformin.3-6Although neither glibenclamide
nor metformin have marketing authorization for their use in
pregnancy, their use as an adjunct therapy in gestational diabetes
has been considered by several guidelines. For example,
glibenclamide has been acknowledged in the Fifth International
Workshop-Conference in Gestational Diabetes Mellitus,7 and
both glibenclamide and metformin are considered in National
Institute for Health and Care Excellence (NICE) guidance8 and
American College of Obstetricians and Gynecologists (ACOG)
practice bulletin.9 Oral agents are an attractive alternative to
insulin for their easier administration, lower cost, and better
acceptance.10 Use of oral agents is increasing, and in some
settings they are the first option when drug treatment is required
for women with gestational diabetes.6 11-13 In a large nationwide
retrospective cohort study in the US including 10 778 women
with drug treated gestational diabetes, use of glibenclamide
increased from 7.4% in 2000 to 64.5% in 2011, becoming the
most common treatment since 2007.12
In recent years, several systematic reviews and meta-analyses
have summarized the published evidence using different
approaches: combining randomized controlled trials and
observational studies addressing glibenclamide,14 performing a
meta-analysis of randomized controlled trials comparing
glibenclamide with insulin,15 combining randomized controlled
trials addressing glibenclamide or metformin versus insulin in
a single meta-analysis,16 and conducting a meta-analysis of
randomized controlled trials comparingmetforminwith insulin.17
In 2013, the meta-analysis by Gui and colleagues, which
included five randomized controlled trials comparingmetformin
with insulin, showed differences favouring metformin in terms
of maternal weight gain and pregnancy induced hypertension
but favouring insulin in terms of gestational age at delivery and
preterm birth.17 A later meta-analysis addressing metformin
versus insulin added a non-randomized controlled trial study.18
In 2014, the meta-analysis of Zeng and colleagues, including
five randomized controlled trials comparing glibenclamide with
insulin, showed differences favouring glibenclamide in terms
of maternal hypoglycaemia but favouring insulin in terms of
birth weight, macrosomia, and neonatal hypoglycaemia.15 As
yet, randomized controlled trials comparing glibenclamide or
metformin with insulin, or metformin with glibenclamide, have
not been addressed in a comprehensive systematic review that
evaluates the most relevant maternal and fetal outcomes.
The aim of the present study was to compare risks and benefits
of insulin, glibenclamide, and metformin in terms of short term
outcomes when used for women with gestational diabetes
requiring drug treatment. By means of a systematic review, we
synthesized the available evidence concerning short term
maternal and fetal outcomes in randomized controlled trials that
compared glibenclamide with insulin, metformin with insulin,
or metformin with glibenclamide in women with gestational
diabetes requiring drug treatment.
Methods
Literature search and study selection
The protocol of this systematic review was registered in
ClinicalTrials.gov (NCT01998113), and endorses PRISMA. A
comprehensive electronic search strategy was conducted in
Medline, Cochrane Central Register of Controlled Trials, and
Embase (see supplementary table 1). The last search update was
performed on 20May 2014. Bibliographies from relevant studies
were reviewed, and authors of potentially eligible studies were
contacted when necessary to request further information
regarding study design or primary outcomes.
Studies were eligible if they fulfilled all the following: (1) they
were randomized controlled trials; (2) subjects were women
with gestational diabetes requiring drug treatment; (3) they
compared glibenclamide with insulin, metformin with insulin,
or metformin with glibenclamide; (4) they provided information
on one or more maternal or fetal outcome; and (5) they were
published as a full paper. The exclusion criterion was a
significant overlap with other articles by the same group.
Data collection and outcomes
We pre-specified maternal and fetal outcomes of interest.
Primary outcomes were defined as those considered relevant or
commonly reported. Primary maternal outcomes were HbA1c
level in the third trimester, severe maternal hypoglycaemia,
pre-eclampsia, total weight gain during pregnancy, caesarean
section, and (for trials comparing metformin v glibenclamide)
treatment failure. Primary fetal outcomes were gestational age
at delivery, preterm birth, birth weight, macrosomia (≥4000 g),
large for gestational age newborn (birth weight >90th centile),
small for gestational age newborn (birth weight <10th centile),
any neonatal hypoglycaemia, and perinatal mortality.
Secondary maternal outcomes were fasting and postprandial
blood glucose, weight gain since study entry, pregnancy induced
hypertension, and induction of labour. Secondary fetal outcomes
were fetal hyperinsulinism (measured as either cord C peptide
or cord insulin), abnormal Apgar score at 1 and 5 minutes,
obstetric trauma, severe neonatal hypoglycaemia (as defined by
authors, or requiring intravenous glucose or admission to the
neonatal intensive care unit), neonatal jaundice, significant
respiratory distress (described as respiratory distress syndrome
or requiring respiratory support), stillbirth, neonatal mortality,
and admission to the neonatal intensive care unit.
Two investigators independently screened abstracts, reviewed
the full text, decided on eligibility, and collected data using a
previously designed form. Discrepancies were solved after
reviewing the source and by consensus with a third investigator.
The risk of bias was assessed at the study level taking into
account the randomization process, quality of allocation
concealment, blinding, selective outcome reporting, sample size
calculation, attrition rates, intention-to-treat analysis, and
comparability of subjects’ baseline characteristics (maternal
age, pre-pregnancy body mass index, fasting plasma glucose
concentration and two hours after oral glucose tolerance test,
gestational age, and HbA1c level at study entry).
19 This
assessment was essentially qualitative, except in the case of
attrition rates where we predefined a quantitative criterion: a
cut-off of 15% both for overall attrition rate and for differences
between treatment groups (unless otherwise foreseen by the
authors). This information concerning risk of bias was used to
perform sensitivity analyses, excluding articles with relevant
weaknesses in trial design or execution. Unbalanced baseline
characteristics alone were not considered an exclusion criterion
for the sensitivity analysis.
Statistical analysis
Outcome data from original studies were pooled into either
relative risks for dichotomous outcomes or mean differences
for continuous outcomes using Review Manager 5.1 software.
Heterogeneity was explored for all the meta-analyses. Analyses
were undertaken using a fixed effects model; in case of
substantial heterogeneity (I2≥50%) a random effects model was
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used. Pooled analyses were also used to compare baseline
characteristics. In the metformin versus glibenclamide
comparison including two studies, we performed a qualitative
assessment of the effects (direction, magnitude, and precision)
in addition to the meta-analysis.
In the metformin versus insulin comparison, the only baseline
characteristic that presented significant and relevant differences
between treatment groups was body mass index. Thus, for this
comparison we performed ameta-regression to explore baseline
body mass index as a source of heterogeneity by means of
meta-regression models. Post hoc meta-regression models were
built for variables known to be influenced by maternal body
mass index and with heterogeneity >10% (weight gain,
caesarean section, macrosomia, and a large for gestational age
newborn), considering the average baseline difference in body
mass index between treatments as the independent factor.
In the three drug comparisons, we calculated average treatment
failure (%) for oral agents. In the metformin versus
glibenclamide comparison, we also calculated the pooled
estimate for treatment failure in terms of risk ratio.
Publication bias was assessed for all analyses after visual
inspection of funnel plots.
Results
The search retrieved 974 abstracts. As depicted in the flow chart
(supplementary figure 1), 15 studies fulfilled our inclusion
criteria—seven comparing glibenclamide with insulin (798
subjects), six comparingmetformin with insulin (1362 subjects),
and two comparing metformin with glibenclamide (349
subjects). The characteristics of the included studies and quality
assessment are described in supplementary tables 2 and 3.
Meta-analysis results for each comparison are presented in tables
1–3⇓⇓⇓. Forest plots for primary outcomes with significant
differences in any of the meta-analyses are shown as
supplementary figure 2, with the exception of those for birth
weight and any neonatal hypoglycaemia, which are displayed
in figures 1⇓ and 2⇓.
Glibenclamide versus insulin
Characteristics of the seven included studies and baseline data
are summarized in supplementary table 2.2 3 20-24 Studies were
performed in the US, Brazil, and India.Most common diagnostic
criteria were those of Carpenter and Coustan and of the World
Health Organization, and blood glucose cut-off values for
initiating drug treatment were similar among trials. The largest
study2 included 404 subjects, while each of the other six included
fewer than 100 participants. Baseline characteristics did not
differ between groups (see supplementary table 4).
All trials were open label, and none had a published protocol.
Randomization procedure, allocation concealment, and sample
size calculation were not available for any of the studies. Three
studies reported one variable less than indicated in the
methods.2 20 24 Two studies had attrition issues: one had a high
balanced attrition, but, as this had been foreseen by the authors,3
the study was not excluded in the sensitivity analysis; the other
study had an unbalanced attrition rate (3/13 (23.1%) v 0/13)
(see supplementary table 3)21 and was excluded in the sensitivity
analysis.
When compared with insulin, glibenclamide was associated
with a higher birth weight (pooled mean difference 109 g (95%
confidence interval 35.9 to 181) and more macrosomia (pooled
risk ratio 2.62 (1.35 to 5.08)) and neonatal hypoglycaemia
(pooled risk ratio 2.04 (1.30 to 3.20)). The average treatment
failure in the glibenclamide group was 6.37% (20/314). None
of the secondary outcomes showed significant differences (table
1⇓). The sensitivity analysis did not affect treatment estimates
in any substantial way (see supplementary table 5), and funnel
plots displayed symmetrical distributions for all the outcomes
with the exception of large for gestational age.
Outcome definition and active ascertainment were not always
provided. In some outcomes such as preterm birth, caesarean
section, birth weight, and Apgar score there is wide agreement
in their definition. In those where definition and detection
protocol can display more differences (neonatal hypoglycaemia,
respiratory distress, jaundice, and admission to the neonatal
intensive care unit), reported definitions and active ascertainment
were reasonably similar with the exception of the protocol to
detect neonatal hypoglycaemia withmeasurements of glycaemia
ranging from two to nine.
In addition to primary and secondary outcomes, maternal
biochemical hypoglycaemia was reported to be higher in the
insulin group by Langer et al,2whereas Ogunyemi et al22 reported
a similar rate in both groups. Ogunyemi et al also described
additional side effects in 6.3% of patients treated with
glibenclamide.
Metformin versus insulin
Characteristics of the six included studies and baseline data are
summarized in supplementary table 2.4 25-29 Studies were
performed in the US, Australia and New Zealand, Finland, Iran,
and Brazil. Several diagnostic criteria were used, and blood
glucose cut-off values for initiating drug treatment were similar
among studies. Metformin and insulin groups were similar in
all baseline characteristics, but prepregnancy body mass index
was significantly higher in the metformin group (pooled mean
difference 0.78 (95% confidence interval 0.15 to1.41), see
supplementary table 4).
All trials were open label, and sample size calculation was
described. Published protocol, randomization procedure, and
allocation concealment were available for most studies. All the
studies reported findings for the outcomes specified in their
protocols. Attritions were lower than 15% and balanced among
groups in all trials. One study was excluded from the sensitivity
analysis25 because of a relevant weakness in trial execution
(when we calculated mean height using the reported weight and
body mass index in the metformin and insulin groups, we
obtained figures of 140 and 160 cm respectively, which is
virtually impossible) (see supplementary table 3).
When compared with insulin, metformin was associated with
less maternal weight gain (pooled mean difference −1.14 kg
(95% confidence interval −2.22 to −0.06)), lower gestational
age at delivery (pooled mean difference −0.16 weeks (−0.30 to
−0.02)), and more preterm birth (pooled risk ratio 1.50 (1.04 to
2.16)). A trend was observed towards a lower rate of any
neonatal hypoglycaemia (pooled risk ratio 0.78 (0.60 to 1.01)).
The average treatment failure in themetformin groupwas 33.8%
(229/678). For secondary outcomes, metformin was associated
with lower postprandial blood glucose (pooled mean difference
−0.14 mmol/L (−0.22 to −0.05)), less maternal weight gain
since study entry (pooled mean difference −1.23 kg (−1.72 to
−0.73)), less pregnancy induced hypertension (pooled risk ratio
0.53 (0.31 to 0.90)), and less severe neonatal hypoglycaemia
(pooled risk ratio 0.62 (0.42 to 0.94)) (table 2⇓). The sensitivity
analysis did not affect treatment estimates in any substantial
way (see supplementary table 6), and funnel plots displayed
symmetrical distributions for all the outcomes, with the
exception of maternal weight gain and weight gain since study
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entry. Outcome definition and active ascertainment were not
always provided. In outcomes where definition and detection
protocol can display more differences, reported definitions and
active ascertainment were reasonably similar, with the exception
of the protocol to detect neonatal hypoglycaemia with
measurements of glycaemia ranging from one to more than six.
Baseline maternal body mass index continued to be higher in
the metformin group in the sensitivity analysis (pooled mean
difference 0.68 (0.05 to1.32)). Baseline differences in body
mass index were not significant in any meta-regression model,
suggesting that this variable is unlikely to be a source of
heterogeneity in the meta-analysis results.
In addition to primary and secondary outcomes, maternal
biochemical hypoglycaemia was not reported in any study.
Additional side effects in the metformin group (mainly
gastrointestinal) were reported in five studies, ranging from
2.5% to 45.7%.4 26-29Nevertheless, patients preferred metformin
over insulin in the two studies that addressed patient
satisfaction.4 25
Metformin versus glibenclamide
Only two trials compared metformin and glibenclamide head
to head, and their characteristics are summarized in
supplementary table 2.5 30 Studies were performed in the US
and Brazil, and diagnostic criteria were those of Carpenter and
Coustan30 and the WHO.5 Blood glucose cut-off values for
initiating drug treatment were lower in one of the trials.5
Metformin and glibenclamide groups were similar in baseline
characteristics with the exception of higher maternal age (pooled
mean difference 1.36 years (95% confidence interval 0.07 to
2.64)) and number of prior pregnancies (pooled mean difference
0.37 pregnancies/patient (0.20 to 0.72)) in the metformin group
(see supplementary table 4).
Both trials were open label and described the randomization
procedure and allocation concealment. Only one of the studies
had a published protocol and described sample size calculation.30
One study reported one variable less than those described in the
methods (macrosomia).5 There were no attritions (see
supplementary table 3), and a sensitivity analysis was not
necessary since no study fulfilled criteria for exclusion.
When compared with glibenclamide, metformin was associated
with less maternal weight gain (pooled mean difference −2.06
kg (−3.98 to −0.14)), lower birth weight (pooled mean
difference −209 g (−314 to −104)), less macrosomia (pooled
risk ratio 0.33 (0.13 to 0.81)), and fewer large for gestational
age newborns (pooled risk ratio 0.44 (0.21 to 0.92)). The average
treatment failure was 26.8% (48/179) in the metformin group
versus 23.5% (40/170) in the glibenclamide group. For
secondary outcomes, metformin was associated with higher
fasting blood glucose during treatment (pooled mean difference
0.15 mmol/L (0.00 to 0.30)) (table 3⇓). Funnel plots displayed
symmetrical distributions for all the outcomes with the exception
of caesarean section. As to outcomes where definition and
detection protocol can display more differences, both authors
reported data on neonatal hypoglycaemia (similar definition,
protocol for detection reported in one study5) and neonatal
intensive care unit stay (not defined in either of the studies).
In the qualitative assessment of birth weight, macrosomia, and
fasting blood glucose (outcomes addressed in both studies and
with significant differences), the direction, magnitude, and
precision of the effects were similar with the exception of a
wider interval for macrosomia in the study of Moore et al.30
In addition to primary and secondary outcomes, maternal
biochemical hypoglycaemia was reported to be similar in both
groups in the study ofMoore et al.30Additional side effects were
not reported.
Discussion
The results of our present study in women with gestational
diabetes requiring drug treatment show that glibenclamide and
metformin do not achieve similar short term outcomes when
compared with each other or when compared with insulin.
Glibenclamide versus insulin
Themain finding was observed when comparing glibenclamide
with insulin. Birth weight was about 100 g higher, neonatal
hypoglycaemia was twofold higher, and macrosomia was more
than twofold higher in the glibenclamide group. The magnitude
of the difference in these outcomes is relevant for clinical
practice. In addition, the higher—although not significant—risk
ratios for large for gestational age and severe neonatal
hypoglycaemia point in the same direction. It is important to
note that neonatal hypoglycaemia and macrosomia are included
among highest priority outcomes in a study specifically
addressing research needs in gestational diabetes.31
Higher birth weight3 15 20 and higher rates of macrosomia3 15 and
neonatal hypoglycaemia15 20 32 with glibenclamide use had
already been reported in individual trials3 20 or meta-analyses,15 32
but these untoward effects have received little attention to date.
For example, the American College of Obstetricians and
Gynecologists (ACOG) practice bulletin on gestational diabetes
in 2013 indicates that current data show no adverse short term
effects from oral diabetic therapy during pregnancy on maternal
or neonatal health but that long term outcomes have yet to be
studied.9 We now report a comprehensive meta-analysis on
randomized controlled trials comparing glibenclamide with
insulin to provide robust estimators for these outcomes.
The main differences between our present meta-analysis on
glibenclamide versus insulin and that by Zeng et al15 are, first,
that we included two additional papers23 24 and, second, that the
outcomes addressed in the two meta-analyses were not
completely coincident. We did not consider four outcomes
included by Zeng and colleagues15 (non-severe maternal
hypoglycaemia, congenital malformations, hypocalcaemia,
polycythaemia), but we considered 17 additional ones (maternal
total weight gain, maternal weight gain since entry, maternal
severe hypoglycaemia, pregnancy induced hypertension,
gestational age at delivery, induction, cord C peptide and insulin,
Apgar score at 1 and 5 minutes, small for gestational age,
obstetric trauma, severe neonatal hypoglycaemia, respiratory
distress, and mortality (stillbirth, neonatal, and perinatal)).
Our meta-analysis confirms the results of Zeng et al,15 but our
interpretation is clearly divergent. Although advising some
caution, Zeng et al conclude that glibenclamide is a convenient
alternative to insulin in developing countries. We consider that
the twofold higher neonatal hypoglycaemia and more than
twofold higher macrosomia in women treated with
glibenclamide are unacceptable; if an alternative to insulin is
required, metformin—with a more favourable short term
profile—would be a better option. Our third meta-analysis,
comparingmetforminwith glibenclamide, provides confirmation
of the untoward effects of glibenclamide.
Even when the few trials addressing cord insulin or C peptide
have not shown any difference, we can only understand the
results in the glibenclamide versus insulin comparison in terms
of more fetal hyperinsulinism in the glibenclamide arm. As
glycaemic control cannot account for this hyperinsulinism, it is
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necessary to consider glibenclamide itself. Reports from Langer
et al do not support a significant maternal to fetal transfer of
glibenclamide2 or its metabolites.33
However Hebert et al34 describe a maternal to fetal ratio for
glibenclamide of 0.7. They attribute these diverging results to
the use of a method with a detection limit of 0.25 ng/mL,34while
that of the method of Langer et al was 10 ng/mL.2 We therefore
consider that maternal to fetal transfer of glibenclamide is the
most likely explanation for the higher birth weight and risk
ratios of macrosomia and neonatal hypoglycaemia observed in
the glibenclamide group.
Metformin versus insulin
The meta-analysis of randomized controlled trials comparing
metformin with insulin showed differences in seven of the 29
analyzed variables, but the magnitudes were smaller than those
for glibenclamide versus insulin. In the metformin group,
maternal outcomes were better in terms of total weight gain,
weight gain since study entry, postprandial blood glucose, and
pregnancy induced hypertension, whereas fetal outcomes were
worse in terms of gestational age at delivery and preterm birth
and better in terms of severe neonatal hypoglycaemia. Among
these variables, weight gain, pregnancy induced hypertension,
and neonatal hypoglycaemia are included as highest priority
outcomes in a study specifically addressing research needs in
gestational diabetes.31 Individual trials had previously reported
significant differences in the above outcomes (postprandial
glycaemia,4 gestational age at delivery,4 preterm birth,4 weight
gain,4 27 weight gain since study entry,4 27 29 neonatal
hypoglycaemia,29 and severe neonatal hypoglycaemia4) with the
exception of pregnancy induced hypertension, that nevertheless
reached significance in a recent meta-analysis.17
The main differences between the meta-analysis by Gui et al17
and the present study are, first, that we included an additional
randomized controlled trial29 and, second, that the outcomes
addressed in the two meta-analyses were not completely
coincident. We did not consider three outcomes included by
Gui et al (congenital malformations, cord pH, and
phototherapy),17 but we considered nine additional ones
(maternal total weight gain and severe hypoglycaemia,
induction, cord C peptide and insulin, Apgar score at 1 minute,
macrosomia, severe neonatal hypoglycaemia, and mortality
(stillbirth, neonatal, perinatal)). Our meta-analysis confirms the
results of Gui et al17 and adds a lower total maternal weight gain
and a lower occurrence of severe neonatal hypoglycaemia in
the metformin group.
It is important to note that, although metformin and insulin
groups in the current study were similar in most baseline
characteristics, prepregnancy body mass index was higher by
0.78 in the metformin group. It is likely that this higher body
mass index influenced outcomes such as pregnancy induced
hypertension,35 pre-eclampsia,35 birth weight,35 large for
gestational age,35 and neonatal hypoglycaemia.36 If treatment
groups had had a similar baseline body mass index, differences
in outcomes could have beenmore apparent (pregnancy induced
hypertension, severe neonatal hypoglycaemia) or become
significant (pre-eclampsia, birth weight, large for gestational
age, any neonatal hypoglycaemia).
Regarding potential mechanisms mediating differences with
metformin use, the lower postprandial blood glucose observed
with metformin (−0.14 mmol/L) seems insufficient to account
for the lower rate in pregnancy induced hypertension and severe
neonatal hypoglycaemia.37 The effect of metformin on maternal
weight gain could be expected considering the effect of
metformin outside pregnancy, while that on pregnancy induced
hypertension could be attributed to improvements in insulin
resistance, inflammation, or endothelial function. The effect of
metformin on gestational age—small, but sufficient to increase
the rate of preterm birth by 50%—is inconsistent with the
slightly better postprandial blood glucose and the reduced rate
of pregnancy induced hypertension. This effect of metformin
on gestational age could be attributed to metformin itself.
However, it is of note that in one report in women with
polycystic ovary syndrome, metformin treatment was associated
with a lower rate of preterm birth,38 and the authors indicated
that underlying mechanism(s) could only be speculated on. It
should also be pointed out that in our study, and contrary to
what might be expected, a lower gestational age at birth in the
metformin group was associated with less neonatal
hypoglycaemia. Again, an independent effect of metformin
could be hypothesized.
Despite the fact that side effects were more common in women
treated with metformin, it was the favoured drug in the studies
addressing preference.
Metformin versus glibenclamide
The meta-analysis of the two randomized controlled trials
comparing metformin with glibenclamide showed differences
in five of the 30 analyzed variables. Differences in total maternal
weight gain, birth weight, macrosomia, and large for gestational
age were roughly the sum of the effects seen in the first two
meta-analyses. However, the results in three outcomes were
unexpected after the findings of the first two comparisons: in
the metformin group, we would expect a lower rate of neonatal
hypoglycaemia, no difference for fasting blood glucose, and a
higher rate of treatment failure. We have no explanation for the
difference in fasting blood glucose, while the lack of significance
for neonatal hypoglycaemia and treatment failure could be due
to the relatively small number of included subjects. The higher
fasting blood glucose in the metformin group (0.15 mmol/L)
cannot account for the differences in clinical outcomes, first,
because it cannot explain the lower maternal weight gain and,
second, because it would have increased outcomes related to
birth weight rather than decrease them. Overall, we consider
the results of this comparison as confirmatory of the maternal
weight gain and outcomes related to birth weight reported in
the first two. The results of the qualitative assessment support
the results of the meta-analysis for outcomes with significant
differences.
Among the variables where significant differences were reached,
maternal weight gain, macrosomia, and large for gestational
age are included as highest priority outcomes in a study
specifically addressing research needs in gestational diabetes.31
In the three meta-analyses, and for most outcomes, definition
and active ascertainment were not an issue. For outcomes where
this could be important, definitions and detection protocol when
provided were reasonably similar with the exception of neonatal
hypoglycaemia. Nevertheless, heterogeneity was very low for
most of these variables.
The main limitation of this study is that we have performed
meta-analyses of aggregated patient data, whereas using
individual patient data would have allowed better adjustment
for baseline characteristics. Its main strength is to be the most
comprehensive systematic review andmeta-analysis addressing
glibenclamide andmetformin versus insulin or versus each other
in the treatment of women with gestational diabetes requiring
drug treatment.
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Conclusion
Oral agents are clearly more attractive than insulin to treat
women with gestational diabetes, but attainment of similar or
better results should be a prerequisite for their use. The results
of the three meta-analyses presented here indicate that, in the
short term at least, this is not the case for glibenclamide (higher
birth weight and more macrosomia and neonatal
hypoglycaemia). For metformin, results were better for maternal
outcomes in terms of weight gain and pregnancy induced
hypertension but uneven for fetal outcomes: more preterm birth
and less severe neonatal hypoglycaemia. It is important to bear
in mind, however, that metformin is associated with a higher
rate of treatment failure and that its long term safety remains
unknown.
As to future research, we consider that: (1) meta-analyses of
individual patient data would allow adjustment for differences
in baseline characteristics, especially important in the
comparison of metformin with insulin; (2) although a definite
proof of glibenclamide producing more fetal hyperinsulinism
is lacking, current evidence discourages further trials using this
drug; (3) studies addressing mechanisms underlying earlier
delivery and less neonatal hypoglycaemia in women treated
with metformin would be of interest.
We conclude that, in the short term, in women with gestational
diabetes requiring drug treatment, glibenclamide is clearly
inferior to both insulin and metformin while metformin (plus
insulin when required) performs slightly better than insulin.
According to these results, glibenclamide should not be used
for the treatment of women with gestational diabetes if
metformin or insulin are available.
We thank Carolyn Newey, author editor that has reviewed the draft
written by the authors. We also thank the authors of randomized
controlled trials who provided the requested information.
Preliminary results of this study have been presented at the 45th Meeting
of the Diabetic Pregnancy Study Group held in Malta in 2013 and at the
XXV meeting of the Sociedad Española de Diabetes held in Pamplona
in 2014; corresponding abstracts were published in the 45th DPSG
abstract book and in Av Diabetol 2014;30(Espec Congr):209.
Contributors: RC is the guarantor of this article. She had full access to
all of the data in the study and takes responsibility for the integrity of
the data and the accuracy of the data analysis. MB, AGP and RC
conceived and designed the study, MB and AGP performed data
acquisition. MB, AGP, IS, MR, IG and RC analysed and interpreted the
data and carried out the statistical analyses. MB, AGP and RC drafted
the manuscript. All authors critically revised the manuscript for important
intellectual content.
Funding: None. The study sponsor is Fundació Institut de Recerca de
l’Hospital de la Santa Creu i Sant Pau; the sponsor was not involved in
the design or execution of the systematic review or in the writing of the
manuscript.
Competing interests: All authors have completed the ICMJE uniform
disclosure form at www.icmje.org/coi_disclosure.pdf and declare: declare
no support from any organisation for the submitted work; no financial
relationships with any organisations that might have an interest in the
submitted work in the previous three years, though MB, AGP, and RC
have received travel grants from Lilly, NovoNordisk, and Sanofi Aventis;
and no other relationships or activities that could appear to have
influenced the submitted work.
Ethical approval: Not required
1 Hunt KJ, Schuller KL. The increasing prevalence of diabetes in pregnancy.Obstet Gynecol
Clin North Am 2007;34:173-99.
2 Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide
and insulin in women with gestational diabetes mellitus. N Engl J Med 2000;343:1134-8.
3 Lain KY, Garabedian MJ, Daftary A, Jeyabalan A. Neonatal adiposity following maternal
treatment of gestational diabetes with glyburide compared with insulin. Am J Obstet
Gynecol 2009;200:501.e501-506.
4 Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the
treatment of gestational diabetes. N Engl J Med 2008;358:2003-15.
5 Silva JC, Fachin DR, Coral ML, Bertini AM. Perinatal impact of the use of metformin and
glyburide for the treatment of gestational diabetes mellitus. J Perinat Med 2012;40:225-8.
6 Jacobson GF, Ramos GA, Ching JY, Kirby RS, Ferrara A, Field DR. Comparison of
glyburide and insulin for the management of gestational diabetes in a large managed
care organization. Am J Obstet Gynecol 2005;193:118-24.
7 Metzger BE, Buchanan TA, Coustan DR, de Leiva A, Dunger DB, Hadden DR, et al.
Summary and recommendations of the Fifth International Workshop-Conference on
Gestational Diabetes Mellitus. Diabetes Care 2007;30(suppl 2):S251-60.
8 National Institute for Health and Care Excellence. Diabetes in pregnancy: management
of diabetes and its complications from pre-conception to the postnatal period. (Clinical
guideline 63.) 2008. www.nice.org.uk/guidance/cg63/.
9 Committee on Practice Bulletins—Obstetrics. Practice bulletin No. 137: gestational diabetes
mellitus. Obstet Gynecol 2013;122:406-16.
10 Coetzee EJ. Pregnancy and diabetes scenario around the world: Africa. Int J Gynaecol
Obstet 2009;104:S39-41.
11 Goh JE, Sadler L, Rowan J. Metformin for gestational diabetes in routine clinical practice.
Diabetic Med 2011;28:1082-7.
12 Camelo Castillo W, Boggess K, Sturmer T, Brookhart MA, Benjamin DK Jr, Jonsson Funk
M. Trends in glyburide compared with insulin use for gestational diabetes treatment in
the United States, 2000-2011. Obstet Gynecol 2014;123:1177-84.
13 Heilmaier C, Thielscher C, Ziller M, Altmann V, Kostev K. Use of antidiabetic agents in
the treatment of gestational diabetes mellitus in Germany, 2008-2012. J Obstet Gynaecol
Res 2014;40:1592-7.
14 Moretti ME, Rezvani M, Koren G. Safety of glyburide for gestational diabetes: a
meta-analysis of pregnancy outcomes. Ann Pharmacother 2008;42:483-90.
15 Zeng YC, Li MJ, Chen Y, Jiang L, Wang SM, Mo XL, et al. The use of glyburide in the
management of gestational diabetes mellitus: a meta-analysis. Adv Med Sci
2014;59:95-101.
16 Dhulkotia JS, Ola B, Fraser R, Farrell T. Oral hypoglycemic agents vs insulin in
management of gestational diabetes: a systematic review andmetaanalysis. Am JObstet
Gynecol 2010;203:457.e1-9.
17 Gui J, Liu Q, Feng L. Metformin vs insulin in the management of gestational diabetes: a
meta-analysis. PloS One 2013;8:e64585.
18 Su DF, Wang XY. Metformin vs insulin in the management of gestational diabetes: a
systematic review and meta-analysis. Diabetes Res Clin Pract 2014;104:353-7.
19 Higgins JPT, Altman DG, Sterne JAC, eds. Chapter 8: Assessing risk of bias in included
studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0 . Cochrane Collaboration, 2011. www.cochrane-handbook.
org.
20 Silva JC, Bertini AM, Taborda W, Becker F, Bebber FR, Aquim GM, et al. [Glibenclamide
in the treatment for gestational diabetes mellitus in a compared study to insulin]. Arq Bras
Endocrinol Metabol 2007;51:541-6.
21 Anjalakshi C, Balaji V, Balaji MS, Seshiah V. A prospective study comparing insulin and
glibenclamide in gestational diabetes mellitus in Asian Indian women. Diabetes Res Clin
Pract 2007;76:474-5.
22 Ogunyemi D, JesseM, DavidsonM. Comparison of glyburide versus insulin in management
of gestational diabetes mellitus. Endocr Pract 2007;13:427-8.
23 Mukhopadhyay P, Bag TS, Kyal A, Saha DP, Khalid N. Oral hypoglycemic glibenclamide:
can it be a substitute to insulin in the management of gestational diabetes mellitus? A
comparative study. J SAFOG 2012;4:28-31.
24 Tempe A, Mayanglambam RD. Glyburide as treatment option for gestational diabetes
mellitus. J Obstet Gynaecol Res 2013;39:1147-52.
25 Moore LE, Briery CM, Clokey D, Martin RW, Williford NJ, Bofill JA et al. Metformin and
insulin in the management of gestational diabetes mellitus: preliminary results of a
comparison. J Reprod Med 2007;52:1011-5.
26 Ijas H, Vaarasmaki M, Morin-Papunen L, Keravuo R, Ebeling T, Saarela T, et al. Metformin
should be considered in the treatment of gestational diabetes: a prospective randomised
study. BJOG 2011;118:880-5.
27 Niromanesh S, Alavi A, Sharbaf FR, Amjadi N, Moosavi S, Akbari S. Metformin compared
with insulin in the management of gestational diabetes mellitus: a randomized clinical
trial. Diabetes Res Clin Pract 2012;98:422-9.
28 Tertti K, Ekblad U, Koskinen P, Vahlberg T, Ronnemaa T. Metformin vs. insulin in
gestational diabetes. A randomized study characterizing metformin patients needing
additional insulin. Diabetes Obes Metab 2013;15:246-51.
29 Spaulonci CP, Bernardes LS, Trindade TC, Zugaib M, Francisco RP. Randomized trial
of metformin vs insulin in the management of gestational diabetes. Am J Obstet Gynecol
2013;209:34.e1-7.
30 Moore LE, Clokey D, Rappaport VJ, Curet LB. Metformin compared with glyburide in
gestational diabetes: a randomized controlled trial. Obstet Gynecol 2010;115:55-9.
31 Bennett WL, Robinson KA, Saldanha IJ, Wilson LM, NicholsonWK. High priority research
needs for gestational diabetes mellitus. J Womens Health 2012;21:925-32.
32 Waugh N, Royle P, Clar C, Henderson R, Cummins E, Hadden D, et al. Screening for
hyperglycaemia in pregnancy: a rapid update for the National Screening Committee.
Health Technol Assess 2010;14:1-183.
33 Elliott BD, Langer O, Schenker S, Johnson RF. Insignificant transfer of glyburide occurs
across the human placenta. Am J Obstet Gynecol 1991;165:807-12.
34 Hebert MF, Ma X, Naraharisetti SB, Krudys KM, Umans JG, Hankins GD, et al. Are we
optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for
better clinical practice. Clin Pharmacol Ther 2009;85:607-14.
35 Siega-Riz AM, Siega-Riz AM, Laraia B. The implications of maternal overweight and
obesity on the course of pregnancy and birth outcomes.Maternal Child Health J 2006;10(5
suppl):S153-6.
36 Garcia-Patterson A, Aulinas A, Maria MA, Ubeda J, Orellana I, Ginovart G, et al. Maternal
body mass index is a predictor of neonatal hypoglycemia in gestational diabetes mellitus.
J Clin Endocrinol Metab 2012;97:1623-8.
37 International Association of Diabetes and Pregnancy Study Groups Consensus Panel,
Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al. International
association of diabetes and pregnancy study groups recommendations on the diagnosis
and classification of hyperglycemia in pregnancy. Diabetes Care 2010;33:676-82.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2015;350:h102 doi: 10.1136/bmj.h102 (Published 21 January 2015) Page 6 of 12
RESEARCH
 o
n
 11 January 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.h102 on 21 January 2015. Downloaded from 
What is already known on this topic
Oral agents are increasingly used to treat gestational diabetes, and current guidelines consider their use even though information on
their safety is limited
Although several meta-analyses of randomized controlled trials addressing oral agents have been published, a comprehensive study
including glibenclamide versus insulin, metformin versus insulin, and metformin versus glibenclamide has not been performed
What this study adds
In the short term, in women with gestational diabetes requiring drug treatment, glibenclamide is clearly inferior to both insulin and
metformin whereas metformin (plus insulin when required) performs slightly better than insulin
38 Vanky E, De Zegher F, Diaz M, Ibanez L, Carlsen SM. On the potential of metformin to
prevent preterm delivery in women with polycystic ovary syndrome - an epi-analysis. Acta
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Tables
Table 1| Meta-analysis of randomized controlled trials comparing outcomes from treatment with glibenclamide v insulin in women with
gestational diabetes
I2 valueP valueRelative risk (95% CI)
Mean difference
(95% CI)
No of patients treated
No of
studiesOutcomes With insulin
With
glibenclamide
Primary outcomes
520.75—−0.03 (−0.25 to 0.18)*2462413HbA1c level at end of third trimester (%)
——0 v 0—2782774Severe maternal hypoglycaemia (%)
00.730.90 (0.51 to 1.61)—2842754Pre-eclampsia (%)
210.38—−0.5 (−1.6 to 0.62)2392332Maternal weight gain (kg)
30.300.89 (0.71 to 1.11)—2972864Caesarean section (%)
140.69—0.05 (−0.18 to 0.28)3913846Gestational age at delivery (weeks)
00.520.87 (0.57 to 1.33)—3253165Preterm birth (%)
00.003—109 (35.9 to181)4043947Birth weight (g)
340.0042.62 (1.35 to 5.08)—3553466Macrosomia (%)
520.171.87 (0.76 to 4.61)*—3233145Large for gestational age (%)
90.971.01 (0.56 to 1.82)—2932844Small for gestational age (%)
00.0022.04 (1.30 to 3.20)—4003867Any neonatal hypoglycaemia (%)
00.651.45 (0.29 to 7.21)—2872773Perinatal mortality (%)
Secondary outcomes
00.33—0.06 (−0.06 to 0.19)2802743Fasting blood glucose (mmol/L)
00.34—0.08 (−0.08 to 0.24)2932844Postprandial blood glucose (mmol/L)
——————0Maternal weight gain since entry (kg)
——————0Pregnancy induced hypertension (%)
——————0Induction (%)
—0.63—0.07 (−0.14 to 0.27)28311Cord C peptide (nmol/L)
00.60—−4.31 (−20.4 to 11.7)2442423Cord insulin (pmol/L)
——————01 minute Apgar score <7 (%)
——————05 minute Apgar score <7 (%)
——0 v 0—77732Obstetric trauma (%)
00.135.31 (0.63 to 44.9)—90813Severe neonatal hypoglycaemia† (%)
00.341.44 (0.68 to 3.06)—2782714Neonatal jaundice (%)
00.390.61 (0.19 to 1.92)—2332312Neonatal respiratory distress syndrome
(%)
00.461.60 (0.46 to 5.49)—3263175Stillbirth (%)
—0.991.01 (0.06 to 16.0)—2512442Neonatal mortality (%)
00.920.97 (0.56 to 1.69)—3063024NICU admission (%)
I2=Heterogeneity. HbA1c= glycated haemoglobin. NICU=neonatal intensive care unit.
*Estimated using a random effects model because I2>50%
†Defined by authors or requiring intravenous glucose or NICU admittance.
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Table 2| Meta-analysis of randomized controlled trials comparing outcomes from treatment with metformin v insulin in women with
gestational diabetes
I2 valueP valueRelative risk (95% CI)
Mean difference
(95% CI)
No of patients treatedNo of
studiesOutcomes With insulinWith metformin
Primary outcomes
240.21—−0.04 (−0.09 to 0.02)5335084HbA1c level at end of third trimester (%)
——0 v 0—2682684Severe maternal hypoglycaemia (%)
00.320.82 (0.56 to 1.20)—6536465Pre-eclampsia (%)
640.04—−1.14 (−2.22 to −0.06)*5054684Maternal weight gain (kg)
170.710.97 (0.85 to 1.12)6846786Caesarean section (%)
00.03—−0.16 (−0.30 to −0.02)6846786Gestational age at delivery (weeks)
00.031.50 (1.04 to 2.16)—6536465Preterm birth (%)
40.26—−31.4 (−86.5 to 23.6)6846786Birth weight (g)
130.800.96 (0.73 to 1.27)—6846786Macrosomia (%)
220.280.88 (0.69 to 1.11)—6536465Large for gestational age (%)
00.530.88 (0.58 to 1.33)—6536465Small for gestational age (%)
00.060.78 (0.60 to 1.01)—6846766Any neonatal hypoglycaemia (%)
00.991.0 (0.14 to 7.12)—6076004Perinatal mortality (%)
Secondary outcomes
490.24—0.04 (−0.03 to 0.11)5275214Fasting blood glucose (mmol/L)
380.002—−0.14 (−0.22 to −0.05)5275214Postprandial blood glucose (mmol/L)
61<0.001—−1.23 (−1.72 to −0.73)*5335654Maternal weight gain since entry (kg)
00.020.53 (0.31 to 0.90)—5575533Pregnancy induced hypertension (%)
460.110.91 (0.81 to 1.02)—5275203Induction (%)
——————0Cord C peptide (nmol/L)
—0.88—7.64 (−92.7 to 108)2342201Cord insulin (pmol/L)
——————01 minute Apgar score <7 (%)
—0.333.06 (0.32 to 29.3)—37036315 minute Apgar score <7 (%)
20.640.86 (0.45 to 1.63)—4774722Obstetric trauma (%)
480.020.62 (0.42 to 0.94)—5275193Severe neonatal hypoglycaemia† (%)
00.470.90 (0.67 to 1.21)—6846776Neonatal jaundice (%)
00.401.30 (0.70 to 2.41)—6346305Neonatal respiratory distress syndrome (%)
00.691.38 (0.27 to 7.02)—6386325Stillbirth (%)
——0 v 0—6065994Neonatal mortality (%)
00.230.87 (0.70 to 1.09)—6386315NICU admission (%)
I2=Heterogeneity. HbA1c= glycated haemoglobin. NICU=neonatal intensive care unit.
*Estimated using a random effects model because I2>50%
†Defined by authors or requiring intravenous glucose or NICU admittance.
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Table 3| Meta-analysis of randomized controlled trials comparing outcomes from treatment with metformin v glibenclamide in women with
gestational diabetes
I2 valueP valueRelative risk (95% CI)
Mean difference
(95% CI)
No of patients treated
No of
studiesOutcomes
With
glibenclamideWith metformin
Primary outcomes
—0.34—−0.11 (−0.34 to 0.12)961041HbA1c level at end of third trimester (%)
——0 v 0—961041Severe maternal hypoglycaemia (%)
00.940.95 (0.28 to 3.25)—1701792Pre-eclampsia (%)
—0.04—−2.06 (−3.98 to
−0.14)
961041Maternal weight gain (kg)
840.461.99 (0.32 to 12.4)*—1701792Caesarean section (%)
870.711.23 (0.42 to 3.54)*—1701792Treatment failure (%)
00.47—−0.11 (−0.40 to 0.19)1701792Gestational age at delivery (weeks)
—0.831.15 (0.32 to 4.17)—961041Preterm birth (%)
0<0.001—−209 (−314 to −104)1701792Birth weight (g)
00.020.33 (0.13 to 0.81)—1701792Macrosomia (%)
—0.030.44 (0.21 to 0.92)—961041Large for gestational age (%)
—0.781.23 (0.28 to 5.36)—961041Small for gestational age (%)
00.680.86 (0.42 to 1.77)—1691782Any neonatal hypoglycaemia (%)
—0.950.92 (0.06 to 14.6)—961041Perinatal mortality (%)
Secondary outcomes
00.04—0.15 (0.00 to 0.30)1701792Fasting blood glucose (mmol/L)
00.74—−0.04 (−0.27 to 0.19)1701792Postprandial blood glucose (mmol/L)
——————0Maternal weight gain since entry (kg)
——————0Pregnancy induced hypertension (%)
——————0Induction (%)
——————0Cord C peptide (nmol/L)
——————0Cord insulin (pmol/L)
—0.520.46 (0.04 to 5.00)—9510311 minute Apgar score <7 (%)
—0.532.77 (0.10 to 67.2)—16917825 minute Apgar score <7 (%)
——————0Obstetric trauma (%)
——————0Severe neonatal hypoglycaemia† (%)
——————0Neonatal jaundice (%)
——————0Neonatal respiratory distress syndrome
(%)
—0.950.92 (0.06 to 14.6)—961041Stillbirth (%)
——0 v 0—951031Neonatal mortality (%)
10.331.52 (0.65 to 3.55)—1691782NICU admission (%)
I2=Heterogeneity. HbA1c= glycated haemoglobin. NICU=neonatal intensive care unit.
*Estimated using a random effects model because I2>50%
†Defined by authors or requiring intravenous glucose or NICU admittance.
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Figures
Fig 1 Forest plots of birth weight in the meta-analyses comparing glibenclamide and metformin with insulin or with each
other in women with gestational diabetes
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Fig 2 Forest plots of any neonatal hypoglycaemia in the meta-analyses comparing glibenclamide and metformin with insulin
or with each other in women with gestational diabetes
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